Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

Courtney D. DiNardo, Ing Soo Tiong, Anna Quaglieri, +26

Blood

DPP8/DPP9 inhibitor-induced pyroptosis for treatment of acute myeloid leukemia

Darren C. Johnson, Cornelius Y. Taabazuing, Marian C. Okondo, +8

Nature Medicine

Hematological MalignancyOncologyDpp8/dpp9 Inhibitor-induced PyroptosisMedicineApoptosis +4

Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy

Chong Chyn Chua, Andrew W. Roberts, John Reynolds, +12

Journal of Clinical Oncology

ImmunologyPharmacotherapyTumor BiologyMyeloid NeoplasiaHematological Malignancy +16

Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias

Rachel Thijssen, Sarah T. Diepstraten, Donia M. Moujalled, +33

Blood

Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia

Donia M. Moujalled, Fiona C. Brown, Chong Chyn Chua, +22

Blood

Hematological MalignancyBax Confer ResistanceMedicineAcute Myeloid LeukemiaMixed-phenotype Acute Leukemia +12

Peptidomimetic blockade of MYB in acute myeloid leukemia

Kavitha Ramaswamy, Lauren Forbes, Gerard Minuesa, +10

Nature Communications

MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia

Fiona C. Brown, Eric Still, Richard P. Koche, +29

Cancer Discovery

Loss-of-function mutations of Dynamin 2 promote T-ALL by enhancing IL-7 signalling

Cédric S. Tremblay, Fiona C. Brown, Michael Collett, +12

Leukemia

InflammationCytokineSignal TransductionAutoimmune DiseaseT-regulatory Cell +11

Inhibition of the CtBP complex and FBXO11 enhances MHC class II expression and anti-cancer immune responses

Kah Lok Chan, Juliana Gomez, Chelisa Cardinez, +23

Cancer Cell

Cancer ImmunosurveillanceImmunologyTumor ImmunityImmunologic MechanismAnti-cancer Immune Responses +7

Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers

Sarah T. Diepstraten, Yuan Yin, John E. La Marca, +14

Cancer Cell